Skip to main content
Top
Published in: Journal of Bone and Mineral Metabolism 2/2012

01-03-2012 | Case Report

Severe hyperparathyroidism in a pre-dialysis chronic kidney disease patient treated with a very low protein diet

Authors: Eriko Ohta, Masanobu Akazawa, Yumi Noda, Shintaro Mandai, Shotaro Naito, Akihito Ohta, Eisei Sohara, Tomokazu Okado, Tatemitsu Rai, Shinichi Uchida, Sei Sasaki

Published in: Journal of Bone and Mineral Metabolism | Issue 2/2012

Login to get access

Abstract

The present report describes a case of a 64-year-old pre-dialysis woman with chronic kidney disease (CKD) stage 5, who developed severe hyperparathyroidism. This patient had been on a very low protein diet (VLPD) to delay the progression of CKD and the need for renal replacement therapy (RRT). Her serum calcium levels were high-normal to slightly high during this time. However, her serum intact parathyroid hormone (PTH) levels increased from 400 to 1160 pg/ml rapidly over a period of 3 months. Serum 1,25-(OH)2D levels were low, and ultrasound of the neck showed three markedly enlarged parathyroid glands exceeding 2 cm. Parathyroidectomy was performed, and all glands showed nodular hyperplasia, which indicated severe secondary hyperparathyroidism leading to tertiary. Severe secondary hyperparathyroidism requiring surgical intervention is usually observed in patients with long-term RRT and is relatively rare in the pre-dialysis patient. In this case, extension of the pre-dialysis period by VLPD may have predisposed this patient to develop severe secondary hyperparathyroidism. Thus, careful monitoring of calcium, phosphorus, and PTH may be necessary in patients treated with VLPD even before renal replacement therapy. Furthermore, initiation of dialysis should not be excessively delayed by strict protein restriction dietary therapy.
Literature
1.
go back to reference Martin KJ, Gonzalez EA (2011) Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat? Clin J Am Soc Nephrol 6:440–446PubMedCrossRef Martin KJ, Gonzalez EA (2011) Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat? Clin J Am Soc Nephrol 6:440–446PubMedCrossRef
2.
go back to reference Takasaki I, Shionoiri H, Yabana M, Takagi N, Kamijo S, Nakatani Y, Umemura S (1999) Severe hyperparathyroidism with hypercalcemia associated with chronic renal failure at pre-dialysis stage. Endocrinol J 46:167–171 Takasaki I, Shionoiri H, Yabana M, Takagi N, Kamijo S, Nakatani Y, Umemura S (1999) Severe hyperparathyroidism with hypercalcemia associated with chronic renal failure at pre-dialysis stage. Endocrinol J 46:167–171
3.
go back to reference Mizumoto D, Watanabe Y, Fukuzawa Y, Aoi N, Yamazaki C (1994) Clinical profile and outcome of primary hyperparathyroidism accompanied by chronic renal failure. Clin Nephrol 42:315–321PubMed Mizumoto D, Watanabe Y, Fukuzawa Y, Aoi N, Yamazaki C (1994) Clinical profile and outcome of primary hyperparathyroidism accompanied by chronic renal failure. Clin Nephrol 42:315–321PubMed
4.
go back to reference Smith DH, Johnson ES, Thorp ML, Yang X, Neil N (2009) Hyperparathyroidism in chronic kidney disease: a retrospective cohort study of costs and outcomes. J Bone Miner Metab 27:287–294PubMedCrossRef Smith DH, Johnson ES, Thorp ML, Yang X, Neil N (2009) Hyperparathyroidism in chronic kidney disease: a retrospective cohort study of costs and outcomes. J Bone Miner Metab 27:287–294PubMedCrossRef
5.
go back to reference Breslau NA (1988) Normal and abnormal regulation of 1,25-(OH)2D synthesis. Am J Med Sci 296:417–425PubMedCrossRef Breslau NA (1988) Normal and abnormal regulation of 1,25-(OH)2D synthesis. Am J Med Sci 296:417–425PubMedCrossRef
6.
go back to reference Kusano K, Segawa H, Ohnishi R, Fukushima N, Miyamoto K (2008) Role of low protein and low phosphorus diet in the progression of chronic kidney disease in uremic rats. J Nutr Sci Vitaminol 54:237–243PubMedCrossRef Kusano K, Segawa H, Ohnishi R, Fukushima N, Miyamoto K (2008) Role of low protein and low phosphorus diet in the progression of chronic kidney disease in uremic rats. J Nutr Sci Vitaminol 54:237–243PubMedCrossRef
7.
go back to reference Silverberg SJ, Vitamin D (2007) Deficiency and primary hyperparathyroidism. J Bone Miner Res 2(22 Suppl):V100–V104CrossRef Silverberg SJ, Vitamin D (2007) Deficiency and primary hyperparathyroidism. J Bone Miner Res 2(22 Suppl):V100–V104CrossRef
8.
go back to reference Silverberg SJ, Shane E, Dempster DW, Bilezikian JP (1999) The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. Am J Med 107:561–567PubMedCrossRef Silverberg SJ, Shane E, Dempster DW, Bilezikian JP (1999) The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. Am J Med 107:561–567PubMedCrossRef
10.
go back to reference Carlson D (2010) Parathyroid pathology: hyperparathyroidism and parathyroid tumors. Arch Pathol Lab Med 134:1639–1644PubMed Carlson D (2010) Parathyroid pathology: hyperparathyroidism and parathyroid tumors. Arch Pathol Lab Med 134:1639–1644PubMed
11.
go back to reference Hakim RM, Lazarus JM (1995) Initiation of dialysis. J Am Soc Nephrol 6:1319–1328PubMed Hakim RM, Lazarus JM (1995) Initiation of dialysis. J Am Soc Nephrol 6:1319–1328PubMed
12.
go back to reference Churchill DN (1997) An evidence-based approach to earlier initiation of dialysis. Am J Kidney Dis 30:899–906PubMedCrossRef Churchill DN (1997) An evidence-based approach to earlier initiation of dialysis. Am J Kidney Dis 30:899–906PubMedCrossRef
13.
go back to reference Cooper BA, Branley P, Bulfone L, Collins JF, Craig JC, Fraenkel MB, Harris A, Johnson DW, Kesselhut J, Li JJ, Luxton G, Pilmore A, Tiller DJ, Harris DC, Pollock CA (2010) A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med 363:609–619PubMedCrossRef Cooper BA, Branley P, Bulfone L, Collins JF, Craig JC, Fraenkel MB, Harris A, Johnson DW, Kesselhut J, Li JJ, Luxton G, Pilmore A, Tiller DJ, Harris DC, Pollock CA (2010) A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med 363:609–619PubMedCrossRef
14.
go back to reference Evans M, Tettamanti G, Nyren O, Bellocco R, Fored CM, Elinder CG (2011) No survival benefit from early-start dialysis in a population-based, inception cohort study of Swedish patients with chronic kidney disease. J Intern Med 269:289–298PubMedCrossRef Evans M, Tettamanti G, Nyren O, Bellocco R, Fored CM, Elinder CG (2011) No survival benefit from early-start dialysis in a population-based, inception cohort study of Swedish patients with chronic kidney disease. J Intern Med 269:289–298PubMedCrossRef
15.
go back to reference Rosansky SJ, Eggers P, Jackson K, Glassock R, Clark WF (2011) Early start of hemodialysis may be harmful. Arch Intern Med 171:396–403PubMedCrossRef Rosansky SJ, Eggers P, Jackson K, Glassock R, Clark WF (2011) Early start of hemodialysis may be harmful. Arch Intern Med 171:396–403PubMedCrossRef
Metadata
Title
Severe hyperparathyroidism in a pre-dialysis chronic kidney disease patient treated with a very low protein diet
Authors
Eriko Ohta
Masanobu Akazawa
Yumi Noda
Shintaro Mandai
Shotaro Naito
Akihito Ohta
Eisei Sohara
Tomokazu Okado
Tatemitsu Rai
Shinichi Uchida
Sei Sasaki
Publication date
01-03-2012
Publisher
Springer Japan
Published in
Journal of Bone and Mineral Metabolism / Issue 2/2012
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-011-0320-6

Other articles of this Issue 2/2012

Journal of Bone and Mineral Metabolism 2/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine